Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Primary Central Nervous System Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective single arm, phase II clinical trial to observe the efficacy and safety
of orelabrutinib combined with pemetrexed in the treatment for patients with
relapsed/refractory primary central nervous system lymphoma.